BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 2, 2016--
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that it will
report third quarter 2016 financial results on Wednesday, November 9,
2016. Following distribution of the earnings release via wire services,
the Ocular Therapeutix management team will host a live conference call
and webcast at 8:30 a.m. Eastern Time to review the Company's financial
results and provide a general business update.
The live webcast can be accessed by visiting the investor section of the
Company’s website at investors.ocutx.com.
Please connect at least 15 minutes prior to the live webcast to ensure
adequate time for any software download that may be needed to access the
webcast. Alternatively, please call 844-464-3934 (U.S.) or 765-507-2620
(International) to listen to the conference call. The conference ID
number for the live call will be 8389302. An archive of the webcast will
be available until November 23, 2016 on the Company’s website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
(NASDAQ: OCUL) is a biopharmaceutical company focused on the development
and commercialization of innovative therapies for diseases and
conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix has submitted an NDA for post-surgical
pain for its lead product candidate, DEXTENZA™ (dexamethasone insert),
which is in Phase 3 clinical development for post-surgical ocular
inflammation and pain and allergic conjunctivitis. OTX-TP (travoprost
insert) is in Phase 3 clinical development for glaucoma and ocular
hypertension. Ocular Therapeutix is also evaluating injectable drug
delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal incisions
following cataract surgery. For additional information about the
Company, please visit www.ocutx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161102005276/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Media
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Sales and
Marketing
scorning@ocutx.com
